Background: Metabolically healthy obesity (MHO) refers to those individuals who do not show cardiometabolic abnormalities. Our aim was to identify potential clinical and metabolic indicators that may help to distinguish between metabolically healthy and unhealthy individuals amongst overweight and obese children and adolescents. Methods: The study involved 246 overweight/obese and 212 normalweight individuals enrolled in the LIFE Child study, aged between 6 and 18 years. Overweight/obese individuals without cardiovascular risk factors (fasting serum lipids, blood pressure, and glucose) were classified as MHO. Individuals meeting 1 or more criteria of cardiovascular risk factors were classified as metabolically unhealthy obesity (MUO). Results: Among the 246 overweight/obese individuals, 173 (70%) were MHO and 73 (30%) were MUO. The MHO individuals were younger, more likely to be male, and had lower BMI SDS. In the logistic regression models, uric acid (UA) SDS (OR 1.61, 95% CI 1.1-2.6, p = 0.004), waist circumference SDS (OR 2.50, 95% CI 1.2-6.4, p = 0.017), and C-peptide (OR 4.05, 95% CI 3.5-91, p = 0.003) were significant indicators of MUO. Conclusion: Our results suggest that nearly one-third of overweight/obese children are already identified as MUO. Serum levels of UA can be used as an indicator of unhealthy obesity in youth, where lower levels of UA indicate a lower risk and higher levels suggest a higher risk of MUO. We note that the relevance of identifying potential indicators remains the first most important step in future clinical research.
Introduction
Excessive body fat during childhood and adolescence instigates the first changes in the metabolism, vessels, and organs, which may lead to severe cardiometabolic complications, such as increased risk of cardiovascular dysfunction, hypertension, dyslipidemia, and type 2 diabetes mellitus [1] . In fact, both overweight and obesity in chil-dren have increased by 47.1% since 1980 [2] . Its multifactorial nature complicates both therapy and prevention, rendering it a major problem and an important challenge for public health around the world [3] . Although the latest studies from several countries worldwide suggest a stabilization trend in the prevalence of obesity, especially among younger children, its prevalence in adolescents continues to increase [4] . Paradoxically, increasing evidence shows that a subgroup of overweight and obese individuals, reported as "metabolically healthy obesity" (MHO), seems to be less prone to have the typical obesityassociated metabolic disorders, in contrast to those with metabolically unhealthy obesity (MUO) [5] . MHO has been identified by a set of favorable metabolic profiles, including preserved insulin sensitivity, the absence of criteria for metabolic syndrome, increased physical activity, low inflammatory indicators, hepatic fat content, and hormonal profile [6] . These factors might differentiate between metabolically healthy and metabolically unhealthy obese individuals. Although MHO has been well studied in adult populations, research focused on children and adolescents is far more scarce [7] . The reported prevalence of MHO in children varies considerably, ranging from 6 to 75%, depending on the classification system used to define this condition [8, 9] . Due to a lack of consensus, the definition of MHO remains controversial [10] . Therefore, it is essential to investigate underlying mechanisms of the metabolically healthy and unhealthy phenotype in overweight and obese individuals [11] . Studies aimed at identifying new biomarkers that may distinguish the different phenotypes of obesity are required since such indicators could become relevant tools for identifying future diseases, making an accurate prognosis and planning intervention strategies [12] .
Over the last years, it has been suggested that further biomarkers, such as serum uric acid (UA), are associated with risks of developing metabolic syndrome, type 2 diabetes mellitus, and incident cardiovascular events [13] . In fact, UA has been reported to be a clinically important marker of inflammation linked to metabolic disorders in seemingly healthy obese individuals [14] . Currently, there is a paucity of recent data concerning the relation among biochemical variables with MHO and MUO in the pediatric population. On the basis of these observations, this study has endeavored (1) to identify potential clinical and metabolic indicators that may help to distinguish between metabolically healthy and metabolically unhealthy phenotypes; (2) to explore the relationship between serum UA levels and metabolic health in overweight and obese children and adolescents. In addition, we hypothesized that serum UA might be an indicator of the development of adverse cardiometabolic outcomes in obese children and adolescents.
Methods

Research Design and Population
The participants' data in the present study were collected from the ongoing "Leipzig Research Centre for Civilization Diseases (LIFE)" Child study of the University of Leipzig, which initiated in 2011. The instruments used for data collection were a combination of examinations and questionnaires addressing demographic issues, personal and family history, anthropometric, and laboratory measurements. Full details have been reported previously [15, 16] . In 801 children and adolescents, serum UA levels were available (LIFE Child cohort). After excluding those who were underweight (body mass index [BMI] standard deviation score [SDS] <-1.28), had missing values on data required for defining metabolic health status, had any chronic diseases, such as type 1 diabetes mellitus, had a diagnosis of liver disease, or were taking any medication that affects glucose or lipid metabolism, 458 individuals aged 6-18 years remained for analysis (239 male and 219 female) (Fig. 1 ). Among these, 45.2% (n = 207) were obese (BMI SDS ≥1.88) and 8.5% (n = 39) were overweight (BMI SDS between 1.28 and 1.88) and they were evaluated alongside a normal-weight control group (46.3%; n = 212) (BMI SDS between -1.28 and 1.28) [17] . Due to the fact that few participants were overweight, we combined overweight and obesity for the analyses. This study was approved by the Ethical Committee of the University of Leipzig under registration No. 264-10-19042010. Written informed consent was obtained from parents or legal guardians of the participants before the children and adolescents were included in the study. Anthropometric and Clinical Measurements Anthropometric and laboratory data were collected by trained health investigators using standardized procedures. BMI was calculated by weight in kilograms divided by the square height in meters (kg/m 2 ). Age-and sex-specific BMI SDS were calculated using the German reference data [17] as recommended by the German Working for Pediatric Obesity Consensus Guideline [18] . Waist circumference (WC), defined as the midpoint between the lowest rib and the upper anterior iliac spine, was measured in centimeters using an inelastic tape. WC SDS was calculated based on German references [19] . The waist-to-height ratio was calculated as WC (cm) divided by height (cm). Pubertal development was assessed according to the definition of the Tanner stage of breast development in girls and genital stage in boys. Pubertal development was divided into 3 pubertal stages (Tanner stage I was classified as prepubertal; Tanner stage II, III, and IV as pubertal; Tanner stage V as postpubertal) [20] . Blood pressure (BP) was measured at the right arm after a 10-min resting period in the supine position. BP was measured 3 times with a 1-min interval, and the average of all measurements was used for analyses [21] . Participants also completed questionnaires related to their demographic characteristics, medical history, alcohol consumption, and dietary habits.
Biochemical Parameters
Fasting venous blood samples were collected from individuals in the LIFE Child study. The measurement of laboratory parameters was performed at the Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics (ILM), University Hospital Leipzig. Total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), aspartate aminotransferase (AST), alanine aminotransferase (ALT) ultraviolet (UV) tests, gamma-glutamyl transferase (GGT), low-density lipoprotein cholesterol (LDL-C), UA, alkaline phosphatase (colorimetric tests), as well as high-sensitive C-reactive protein (hs-CRP) (latex-enhanced immunoturbidimetric test) were analyzed in serum samples with reagent from Roche Diagnostics using Cobas 8000 System according to the manufacturer's protocol (Roche Diagnostics GmbH, Mannheim, Germany). Serum cystatin C (CysC) was analyzed using the turbidimetric immunoassay (PETIA) Tina-quant ® Cystatin C (Roche Diagnostics). An oral glucose tolerance test (OGTT) was performed in all individuals according to the established recommendations [22] . OGTT-derived laboratory data (insulin and glucose concentrations) were drawn at baseline and after 15, 30, 60, 90, and 120 min. Insulin measurement was performed using the fully automated immunoassay systems of Liaison (Diasorin, Dietzenbach, Germany) and Cobas ECLIA-test on Cobas 8000 e602 (Roche, Mannheim, Germany). Both assays were adjusted for the 1.IRP WHO reference standard. Intra-assay and inter-assay coefficients were below 5.7% [23] . Insulin sensitivity was examined by the homeostasis model assessment index (HOMA-IR) [24] , which was calculated using the following formula:
The whole-body insulin sensitivity index (WBISI) was determined using glucose and insulin values during an OGTT applying the Matsuda calculation [25] .
Defining the Metabolic Health Status
For the purpose of defining the metabolic status, the overweight/obese children and adolescents were divided into two groups (i.e., metabolically healthy or metabolically unhealthy status) according to the following criteria (see online suppl. Table 1; see www.karger.com/doi/10.1159/000490113 for all online suppl. material). Individuals with the presence of at least 1 of the following cardiovascular risk factors were classified as MUO: dyslipidemia, defined as (i) serum triglycerides > 95th percentile or (ii) serum HDL-C < 5th percentile according to the American Academy of Pediatrics [26] ; hypertension, defined as (iii) BP > 95th percentile for height, sex, and age [27] ; impaired fasting glucose (IFG), defined as (iv) fasting serum glucose ≥5.6 mmol/L. On the contrary, MHO status was based on the absence of hypertension, dyslipidemia, and IFG following the definition of Prince et al. [8] . The parameters used to define the metabolic health status were standardized because of age dependence. In addition, we used the 95th percentile as the cutoff for the aforementioned cardiovascular risk factors.
Statistical Analysis
Gaussian distribution of all variables was checked using the Shapiro-Wilk test in addition to graphical methods. All data are reported as mean ± standard deviation (if normally distributed), and median and interquartile range (if non-normally distributed). Categorical data are presented as number (n) and percentage (%). Differences among groups were tested using the χ 2 test for categorical variables and the Mann-Whitney-Wilcoxon test or t test for continuous variables, when appropriate, with a 95% confidence interval (95% CI) and the risk difference between the MHO and MUO groups. We used hierarchical linear regression analysis to evaluate the strength of the relationship between serum UA concentrations and cardiovascular risk factors. All statistical models were adjusted for age and sex. For overweight/obese individuals, logistic regression analysis was performed to assess the association between clinical and metabolic variables as independent variables and metabolically unhealthy status as the dependent variable, controlled for age, sex, pubertal stage, and BMI SDS. Furthermore, logistic regression analyses were performed including gender, age, pubertal stage, WC, UA, C-peptide, hs-CRP, and albumin in order to identify significant indicators of MUO. The regression coefficients are presented as odds ratios (ORs) with 95% CI. In addition, all analyses were performed both including and excluding the overweight category; since our analyses generated similar results, all children with BMI SDS ≥1.28 were included in the final analyses. In order to remove the age dependence, we standardized some parameters such as fasting serum glucose, HDL-C, triglycerides, as well as UA levels using a LMS-type method (LMSP) implemented in the package gamlss [28] . The age-and sex-specific percentiles were found preferable, especially in young children. All results with a p value < 0.05 were considered to be statistically significant. Data analysis was performed using the statistical software R (version 3.1.2, R Core Team, Vienna, Austria) [29] .
Results
Anthropometric and metabolic characteristics of the study population are displayed in Table 1 . The presented data consist of 246 overweight/obese and 212 normalweight children and adolescents (mean age 11.1 ± 2.8 years, 52% male). The mean BMI SDS was -0.04 ± 0.68 in normal-weight and 2.32 ± 0.52 in overweight/obese chil-DOI: 10.1159/000490113 dren. 41% of them were classified as prepubertal, 47% were pubertal, and 12% were postpubertal. Based on the cardiovascular risk factors, the overweight/obese individuals were classified into two groups: 173 (38.0% of the total study sample) MHO (no criteria of cardiovascular risk factors) and 73 (16.0%) MUO (presence of 1 or more criteria of cardiometabolic risk factors). These two groups were compared to the control group (212 [46.0%] normal-weight individuals). Among the cardiovascular risk factors in the MUO individuals, hypertriglyceridemia was the most frequent (in 54.2% of the individuals), followed by low serum HDL-C (45.8%), hypertension (19.5%), and IFG (14.7%). The MHO individuals were more often prepubertal than the MUO individuals. As expected, the MUO group had a significantly higher median BMI SDS than the MHO group (Table 1) . Circulating concentrations of UA SDS, C-peptide, and hs-CRP were significantly higher in the MUO than in the MHO group. Additionally, CysC levels were significantly higher in the controls than in the MHO and MUO groups, whereas no significant difference was found between the MHO and MUO groups. Markers of liver function, including ALT, AST, and alkaline phosphatase, were similarly increased in the MHO and MAO groups, exhibiting no differences between them, with the exception of GGT levels, which were significantly higher in the MUO than in the MHO group. The used parameters defining the metabolic health status are summarized in Table 2 . The MUO group showed significantly higher triglyceride SDS, glucose SDS, as well as systolic and diastolic BP SDS than the MHO group. As expected, glucose metabolism was altered in the MUO group as indicated by increased insulin levels and reduced WBISI with normal glycemia compared to the MHO group. Anthropometric and bio- chemical characteristics of all study participantsare presented in online supplementary Table 2 . MUO children showed significantly increased LDL-C paired with reduced HDL-C SDS when compared to MHO children. Hematological indicators, including hemoglobin, red blood cells, platelets, and white blood cells, were increased in the MUO compared to the MHO group, although no significant differences were found between both groups. Levels of testosterone and hormone binding globulin (SHBG) were higher in the MHO than in the MUO group, whereas levels of estradiol were significantly lower in the MHO than in the MUO group. However, after stratifying the analyses by Tanner stage to avoid a bias caused by the different age distributions of the MHO and MUO groups, the difference was only significant for Tanner 1 stage, where the MHO group showed significantly lower values of estradiol. The results of the hierarchical regression analyses were incorporated to further examine the relationship between serum UA and the parameters used to define the metabolic health status. They are summarized in Table 3 . UA serum concentrations were associated with serum triglyceride SDS, systolic BP, CysC, and Cpeptide. Furthermore, UA SDS was negatively associated with serum HDL SDS. However, we did not find a significant effect of glucose SDS on UA serum levels. Additionally, a logistic regression analysis was performed to identify indicators of the MUO phenotype as shown in Table 4 . Based on the relevant clinical and metabolic variables shown in Table 1 , the set of independent variables like WC, UA, C-peptide, albumin, and hs-CRP were included in the logistic regression models. Variables used for defining the MUO were not included in the logistic regression analysis. In conclusion, higher levels of C-peptide, WC SDS, UA SDS, and pubertal stage were identified as significant indicators of the MUO phenotype. However, no significant effect of sex was found. Higher levels of hs-CRP and albumin were nonsignificant MUO indicators when controlled for age, gender, pubertal stage, and BMI SDS (Table 4) .
Discussion
This study was designed to identify potential clinical and metabolic indicators that may distinguish between metabolically healthy and metabolically unhealthy phenotypes in overweight and obese children and adoles- Data are presented as n (%), mean ± SD, median (interquartile range), or item risk difference (RD) between the MHO and MUO groups with confidence interval (CI). MHO, metabolically healthy obesity; MUO, metabolically unhealthy obesity; HDL-C, high-density lipoprotein cholesterol; SDS, standard deviation score; BP, blood pressure. Comparisons were analyzed by a Mann-Whitney-Wilcoxon test or t test depending on the distribution of data.
a p values for normal-weight controls versus MHO versus MUO. b p values for MHO versus MUO. cents. The results associating serum UA levels with the MUO status in youth are of particular interest, considering that such data were scarcely available up to now. Our study yielded several important findings:
(i) Regarding cardiometabolic characteristics, the MHO children were identified to be younger and less overweight in terms of BMI SDS and to have lower WC, lower insulin resistance index (HOMA), better insulin sensitivity, and lower levels of proinflammatory markers. Such results, which are supported by other studies [30, 31] , may indicate that a subset of overweight/obese children is at relatively low cardiometabolic risk despite possessing a high amount of body fat [32] . Interestingly, concerning the liver profile, the concentrations of ALT and AST were not significantly different between the MHO and MUO children. In contrast to our results, it has been reported that ALT and AST serum concentrations have been significantly different between the MHO and MUO groups [33] . These findings could also be attributed to a healthier constitution, younger age, effects of the ethnicity, or smaller sample size of studied participants. However, a study from Canada found a significant difference in the levels of GGT in the MHO compared to the MUO group [34] , as in the present study.
(ii) Another point of interest is that there were higher proportions of MHO (38.5%) in overweight/obese children and adolescents than described by other authors who evaluated obesity in the pediatric age [35, 36] . For instance, a recent study examining Chinese children and adolescents aged 6-18 years found that prevalence rates were 3.9 and 36.7% using 2 different MHO criteria defined by insulin resistance and cardiometabolic parameters, respectively [37] . Using the same MHO criteria as in the present study, a recently published German study on the effect of pubertal status revealed that a large proportion of obese children (49.3%) exhibited a MHO status [38] . It is likely that the high variability in reported MHO prevalence could be explained by the lack of a standard definition of MHO, specific cutoff values, small sample sizes, different age ranges, as well as behavioral differences between populations [39] [40] [41] .
(iii) A comprehensive logistic regression model identified C-peptide, WC SDS, UA SDS, and pubertal stage as indicators of the MUO status. The current study demonstrated significantly higher levels of C-peptide and insulin in the MUO group, when compared to MHO, indicating an increased β-cell load. This result might indicate early changes in the glucose metabolism of obese children which could be associated with the reduction of insulin sensitivity, as implied by the increased HOMA-IR and the reduced WBISI. Previously published results have shown C-peptide to be associated with insulin resistance, cardiometabolic abnormalities belonging to the metabolic syndrome, dyslipidemia, hypertension, hyperuricemia, and type 2 diabetes mellitus in both obese children and adults [42, 43] . Cardellini et al. [44] demonstrated an important role of C-peptide levels in the chemotactic effect on the inflammatory cells and suggested that it promotes the onset of atherosclerosis. To the best of our knowledge, this is the first study addressing C-peptide as potential indicator of MUO in overweight/obese children and adolescents. In our study, UA was found to be a significant indicator of MUO status after adjusting for age, sex, pubertal status, and BMI SDS. These findings are in agreement with those recently obtained by 2 Austrian authors, who examined overweight/obese children and adolescents and have shown that higher serum UA levels were a significant predictor of metabolically unhealthy status in young populations [36, 45] . In youth, serum UA increases progressively from an early age with body growth and a plateau around 15-17 years [46] . In our study, concentrations were significantly higher in overweight/obese children than in their normal-weight peers. This may be of particular significance for overweight/obese individuals who may ex- hibit chronic long-term hyperuricemia. In fact, increased UA levels may contribute to endothelial dysfunction by instigating antiproliferative effects on endothelium and impairing nitric oxide production; therefore, it has been associated with the risk of cardiovascular disease [47] . In this study, we found that UA was strongly associated with BP. A biological explanation for this result is supported by animal models, which showed that after the onset of hyperuricemia, hypertension occurs. This indicates that the reduction of nitric oxide in the renal macula and the direct stimulation of the renin-angiotensin system are probably the mechanisms to cause vasoconstriction and, therefore, increase BP [48] . According to our findings, MUO is characterized by higher albumin and CysC levels as compared to MHO. In addition, CysC, albumin, and UA were found to be sensitive in the identification of mild reductions in kidney function and could potentially identify young individuals at high risk for the future development of cardiometabolic diseases [49, 50] . These facts highlight that the association among UA levels and cardiometabolic disorders might be a relevant area of research, recognizing the implications of the discovery of potential new indicators and therapeutic targets in individuals with a metabolically unhealthy phenotype.
Furthermore, in our study, the pubertal children had higher odds of being of MUO phenotype. Reinehr et al. [38] showed that entering puberty doubles the risk of switching from MHO to MUO. The difference between pubertal stage and cardiometabolic alterations may be attributable to the physiological changes of body composition and the influence of sex hormones during puberty development [51] .
The major strength of this study is the description of a comprehensive clinical and metabolic analysis of MHO and MUO children and adolescents. However, despite our innovative findings, our study has the following limitations: First, the cross-sectional design of the study could not reveal any causal relationships between the metabolic health status and the investigated indicators. Further assessment of the influence of cardiovascular risk factors when obese children enter puberty is necessary. Second, it is essential to reproduce this study in a longitudinal research among different young populations. Furthermore, our study had a limited sample size, and therefore our observations need to be confirmed in a bigger cohort. Lastly, there is no standard definition of MHO. In conclusion, our study is one of the few to suggest that high UA levels increase the likelihood of MUO. Future longitudinal studies in larger populations are required to confirm that UA is an indicator of metabolic phenotypes associated with obesity, and that it may represent a useful indicator to identify children with increased cardiometabolic risk.
